Page last updated: 2024-08-04 07:52:04
ly2605541
Description
LY2605541: an insulin lispro analog with polyethylene glycol covalently attached to lysine B28 via a urethane linkage [MeSH]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 168324442 |
| MeSH ID | M0592875 |
Synonyms (1)
| Synonym |
|---|
| ly2605541 |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (63.64%) | 5.53% |
| Reviews | 2 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (18.18%) | 84.16% |
Related Drugs (4)
Drugs Researched Together (4)
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| lactic acid | 2-hydroxy monocarboxylic acid | algal metabolite; Daphnia magna metabolite | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| c-peptide | 2014 | 2014 | 10.0 | medium | 1 | 0 | 0 | 0 | 1 | 0 | |||
| insulin glargine | 2012 | 2014 | 10.3 | high | 5 | 0 | 0 | 0 | 6 | 0 | |||
| insulin degludec | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
Related Conditions (14)
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Autoimmune Diabetes | 0 | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Body Weight | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Chronic Kidney Failure | 0 | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Diabetes Mellitus, Adult-Onset | 0 | 2012 | 2014 | 10.3 | high | 5 | 0 | 0 | 0 | 7 | 0 | |
| Diabetes Mellitus, Type 1 | 0 | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Diabetes Mellitus, Type 2 | 0 | 2012 | 2014 | 10.3 | high | 5 | 0 | 0 | 0 | 7 | 0 | |
| Fasting Hypoglycemia | 0 | 2014 | 2014 | 10.0 | medium | 4 | 0 | 0 | 0 | 4 | 0 | |
| Hypoglycemia | 0 | 2014 | 2014 | 10.0 | medium | 4 | 0 | 0 | 0 | 4 | 0 | |
| Kidney Failure | 0 | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Kidney Failure, Chronic | 0 | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Renal Insufficiency | 0 | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Weight Gain | 0 | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Weight Loss | 0 | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Weight Reduction | 0 | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
Pharmacokinetics (3)
| Article | Year |
|---|---|
| Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function. Clinical pharmacology in drug development, , Volume: 5, Issue:3 | 2016 |
| Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. Journal of clinical pharmacology, , Volume: 54, Issue:7 | 2014 |
| Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, , Volume: 16, Issue:4 | 2014 |
Bioavailability (1)
| Article | Year |
|---|---|
| Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. Journal of clinical pharmacology, , Volume: 54, Issue:7 | 2014 |
Dosage (2)
| Article | Year |
|---|---|
| A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin. Diabetes technology & therapeutics, , Volume: 16, Issue:8 | 2014 |
| Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, , Volume: 16, Issue:4 | 2014 |